China SXT Pharmaceuticals, Inc.
SXTC evidence brief
What we can confirm
- Market Cap:
- $135K
What it means
What to watch
Prepared research question
What matters most for SXTC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SXTC
China SXT Pharmaceuticals, Inc. (SXTC) is a China-based specialty pharmaceutical company focused on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements.
Key risk: Shareholder dilution risk
Market Cap
$135K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
China SXT Pharmaceuticals, Inc. (SXTC) is a China-based specialty pharmaceutical company focused on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements.
- Cash & equivalents of $28.2M as of 2026-03-31 [sec].
- Closed a $12 million registered direct offering in October 2026, selling 8 million Class A ordinary shares at $1.50 per share [news · 2026-10-08].
- Effected a 1-for-80 share consolidation effective August 10, 2026 [news · 2026-08-05].
- Launched a strategic AI Insights Initiative in January 2026 to optimize its Traditional Chinese Medicine portfolio and explore AI-supported clinic deployments [news · 2026-01-08].
What works
- The company has a cash position of $28.2M as of 2026-03-31, providing a financial cushion for operations and strategic initiatives [sec].
- It has successfully raised $22 million through two registered direct offerings in 2026 ($10M in January and $12M in October), indicating institutional investor interest [news · 2026-01-14] [news · 2026-10-08].
- The company is proactively exploring AI integration across its supply chain and clinic deployment, which could enhance operational efficiency and market analysis [news · 2026-01-08] [news · 2026-01-15].
What to weigh
- The October 2026 offering involved selling 8 million shares at $1.50 each, which could result in significant shareholder dilution [news · 2026-10-08].
- The company executed a 1-for-80 share consolidation in August 2026, often a sign of low share price and potential delisting risk [news · 2026-08-05].
- Total debt is low at $1.0M as of 2026-03-31, but the company's accumulated deficit and net income/loss figures are not disclosed in the provided chunks, leaving profitability unclear [sec].
From the filings
Quoted directly from source documents.
October 2026 registered direct offering details
“China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering.”
News · October 8, 2026
AI Insights Initiative launch
“China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements”
News · January 8, 2026
Risks & what to watch (3)›
Key risks
- Shareholder dilution risk — October 2026 offering of 8M shares at $1.50 each may significantly dilute existing shareholders [news · 2026-10-08].
- Low share price / delisting risk — 1-for-80 reverse stock split in August 2026 suggests low share price, potentially indicating delisting risk [news · 2026-08-05].
- Profitability unclear — No net income/loss or accumulated deficit figures provided; financial health beyond cash position is unknown [sec].
What to watch
- Impact of the $12M October 2026 offering on share price and dilution [news · 2026-10-08].
- Progress and outcomes of the AI Insights Initiative announced in January 2026 [news · 2026-01-08].
- Any future financial filings disclosing net income/loss and accumulated deficit [sec].
- Market reaction to the 1-for-80 share consolidation effective August 10, 2026 [news · 2026-08-05].
Sources: News · Generated October 13, 2026 · How we verify sources →
Run China SXT Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available China SXT Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 22, 2026- % of float
- 0.3%
- Days to cover
- 0.0
- Shares short
- 3,264
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SXTC short interestFrequently asked questions
What is the AI investment thesis for China SXT Pharmaceuticals, Inc.?
China SXT Pharmaceuticals, Inc. (SXTC) is a China-based specialty pharmaceutical company focused on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements.
Who is the CEO of China SXT Pharmaceuticals, Inc.?
Mr. Feng Zhou is the chief executive officer of China SXT Pharmaceuticals, Inc. (SXTC).
Where is China SXT Pharmaceuticals, Inc. headquartered?
China SXT Pharmaceuticals, Inc. (SXTC) is headquartered in Taizhou, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.